Perifosine (KRX-0401)

Mechanism of action

AKT and PI3K inhibitor

Preliminary data

Hodgkin lymphoma

1. Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S, Russo D, Marchianò A, Sorasio R, Dodero A, Farina L, Giordano L, Di Nicola M, Anichini A, Corradini P, Gianni AM. Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. Clin Cancer Res. 2014 Sep 19. [Epub ahead of print] link to original article PubMed

History of changes in FDA indication

• 9/3/2009: Received FDA orphan drug designation for treatment of multiple myeloma.
• 7/9/2010: Received FDA orphan drug designation for treatment of neuroblastoma.